AveXis (AVXS) Stake Lessened by Eaton Vance Management

Eaton Vance Management decreased its holdings in AveXis (NASDAQ:AVXS) by 16.0% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 49,057 shares of the company’s stock after selling 9,324 shares during the quarter. Eaton Vance Management owned 0.13% of AveXis worth $6,062,000 as of its most recent filing with the SEC.

Several other large investors have also added to or reduced their stakes in the company. Prudential Financial Inc. boosted its stake in AveXis by 10.3% during the first quarter. Prudential Financial Inc. now owns 2,796 shares of the company’s stock valued at $346,000 after buying an additional 262 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in AveXis by 29.2% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,603 shares of the company’s stock valued at $198,000 after buying an additional 362 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in AveXis by 57.5% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,241 shares of the company’s stock valued at $137,000 after buying an additional 453 shares in the last quarter. Emory University boosted its stake in AveXis by 3.4% during the fourth quarter. Emory University now owns 18,474 shares of the company’s stock valued at $2,045,000 after buying an additional 607 shares in the last quarter. Finally, American Century Companies Inc. boosted its stake in AveXis by 4.1% during the first quarter. American Century Companies Inc. now owns 18,534 shares of the company’s stock valued at $2,290,000 after buying an additional 732 shares in the last quarter. 84.14% of the stock is owned by institutional investors.

Several research analysts recently weighed in on AVXS shares. Mizuho started coverage on AveXis in a research note on Monday, February 12th. They set a “buy” rating and a $147.00 target price for the company. UBS set a $143.00 price target on AveXis and gave the company a “buy” rating in a research report on Wednesday, February 28th. They noted that the move was a valuation call. BidaskClub upgraded AveXis from a “hold” rating to a “buy” rating in a research report on Tuesday, February 27th. Morgan Stanley set a $129.00 price target on AveXis and gave the company a “buy” rating in a research report on Tuesday, March 6th. Finally, William Blair reiterated a “buy” rating on shares of AveXis in a research report on Saturday, March 3rd. One analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and six have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $123.90.

Shares of AveXis opened at $217.83 on Friday, MarketBeat reports. The stock has a market capitalization of $8.02 billion, a P/E ratio of -29.92 and a beta of 1.55. AveXis has a 1 year low of $65.54 and a 1 year high of $217.94.

AveXis (NASDAQ:AVXS) last announced its quarterly earnings data on Wednesday, May 9th. The company reported ($6.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.32) by ($2.88). analysts predict that AveXis will post -9.69 earnings per share for the current year.

In related news, insider Brian K. Kaspar sold 15,000 shares of the stock in a transaction dated Thursday, March 1st. The stock was sold at an average price of $126.15, for a total value of $1,892,250.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Sukumar Nagendran sold 1,780 shares of the stock in a transaction dated Thursday, March 1st. The stock was sold at an average price of $126.19, for a total value of $224,618.20. The disclosure for this sale can be found here. Over the last three months, insiders sold 46,780 shares of company stock valued at $5,801,268. Company insiders own 18.60% of the company’s stock.

AveXis Company Profile

AveXis, Inc, a clinical-stage gene therapy company, engages in developing and commercializing treatments for patients suffering from rare and life-threatening neurological genetic diseases. Its initial product candidate is AVXS-101, a gene therapy product candidate that has completed Phase I clinical trial for the treatment of spinal muscular atrophy Type 1.

Institutional Ownership by Quarter for AveXis (NASDAQ:AVXS)

Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply